- Category: Press Releases
- 03 October 2013
Study finds non-invasive ultrasound scan more accurate than MRI and PSA
CHICAGO--(BUSINESS WIRE)--Prostate cancer can be detected simply and more accurately with a radiation-free, non-invasive screening test, according to findings announced today at an international physician conference.
The findings, reported at the International Contrast Ultrasound Society (ICUS) annual conference, found contrast-enhanced ultrasound imaging (CEUS) exams can provide more accurate results than either MRI, PSA or conventional ultrasound imaging.
"The accuracy of MRI in diagnosis is very limited and it misses a significant number of cancerous tumors," according to Hessel Wijkstra, Ph.D., a professor at Eindhoven University of Technology and a research scientist at AMC University Hospital in Amsterdam in the Netherlands. "In addition, PSA testing is inaccurate and generates large numbers of false negatives and false positives," he added.
Prostate cancer is the number one cancer in men, and the potential impact of this is huge for male patients, according to Wijkstra.
"CEUS is less expensive, more accurate, more accessible and does not use radiation," added Stephanie Wilson, a radiologist from the University of Calgary and Co-President of ICUS.
Wijkstra said that the lack of accuracy in the localization of prostate cancer limits patients to radical treatment options, such as operations and the use of radiation. "These treatments can have serious side effects, including impotence, incontinence, and a debilitating effect on the patient's quality of life," he added.
While the ultrasound contrast agents Definity (Lantheus Medical Imaging) and Optison (GE Healthcare) are only approved for use in the United States for cardiac imaging, they and other agents are used widely in Europe and elsewhere for imaging tumors and organ systems throughout the body. Additional applications of these ultrasound contrast agents are under review worldwide.